Elicio Therapeutics
Focus: Elicio Therapeutics is a Boston-based oncology-focused biotech specializing in HPV-induced cancer treatments with a pipeline of immunotherapy candidates. The company is clinical-stage with three active trials spanning Phase 1 and Phase 1/2 development.
Profile data last refreshed 13h ago · AI intelligence enriched 1w ago
Open Jobs
1
Should You Work at Elicio Therapeutics?
AI assessmentSuitable for early-career oncology researchers or immunotherapy specialists willing to accept pre-revenue risk for focused pipeline exposure and potential equity upside.
Why Work Here
- Focused oncology pipeline with recent positive data: May 2026 pancreatic cancer trial showed fewer disease progressions and deaths than projected, validating core therapeutic approach
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ELI-002 7P
Pancreatic Ductal AdenocarcinomaClinical Trials (1)
NCT07083479Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma
N/AHelp build intelligence for Elicio Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.